CoronaHiT: High throughput sequencing of SARS-CoV-2 genomes by Baker, Dave J. et al.
CoronaHiT: High throughput sequencing of SARS-CoV-2 1 
genomes 2 
Dave J. Baker1,*, Alp Aydin1,*, Thanh Le-Viet1, Gemma L. Kay1,  Steven Rudder1, 3 
Leonardo de Oliveira Martins1, Ana P. Tedim1,2, Anastasia Kolyva1,3, Maria Diaz1,  4 
Nabil-Fareed Alikhan1, Lizzie Meadows1, Andrew Bell1, Ana Victoria Gutierrez1, 5 
Alexander J. Trotter1,4, Nicholas M. Thomson1, Rachel Gilroy1, Luke Griffith4, Evelien 6 
M. Adriaenssens1, Rachael Stanley3, Ian G. Charles1,4, Ngozi Elumogo1,3, John Wain1,4, 7 
Reenesh Prakash3, Emma Meader3, Alison E. Mather1,4, Mark A. Webber1,4,  Samir 8 
Dervisevic3, Andrew J. Page1,*,+ and Justin O’Grady1,4,*,+ 9 
  10 
1      Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK. 11 
2      Grupo de Investigación Biomédica en Sepsis - BioSepsis. Hospital Universitario Rio 12 
Hortega/Instituto de Investigación Biomédica de Salamanca (IBSAL), 13 
Valladolid/Salamanca, Spain. 14 
3      Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY, UK. 15 
4      University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK. 16 
*Contributed equally 17 
+Corresponding authors: andrew.page@quadram.ac.uk (bioinformatics); 18 
justin.ogrady@quadram.ac.uk (sequencing) 19 
Keywords:  SARS-CoV-2, Nanopore, Sequencing, NGS, Genome, Genetic, multiplexing, 20 
ARTIC21 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 





The COVID-19 pandemic has spread to almost every country in the world since it started 23 
in China in late 2019. Controlling the pandemic requires a multifaceted approach 24 
including whole genome sequencing to support public health interventions at local and 25 
national levels. One of the most widely used methods for sequencing is the ARTIC 26 
protocol, a tiling PCR approach followed by Oxford Nanopore sequencing (ONT) of up 27 
to 96 samples at a time. There is a need, however, for a flexible, platform agnostic, 28 
method that can provide multiple throughput options depending on changing 29 
requirements as the pandemic peaks and troughs. Here we present CoronaHiT, a method 30 
capable of multiplexing up to 96 small genomes on a single MinION flowcell or >384 31 
genomes on Illumina NextSeq, using transposase mediated addition of adapters and PCR 32 
based addition of barcodes to ARTIC PCR products. We demonstrate the method by 33 
sequencing 95 and 59 SARS-CoV-2 genomes for routine and rapid outbreak response 34 
runs, respectively, on Nanopore and Illumina platforms and compare to the standard 35 
ARTIC LoCost nanopore method. Of the 154 samples sequenced using the three 36 
approaches,  genomes with ≥ 90% coverage (GISAID criteria) were generated for 64.3% 37 
of samples for ARTIC LoCost, 71.4% for CoronaHiT-ONT, and 76.6% for CoronaHiT-38 
Illumina and have almost identical clustering on a maximum likelihood tree. In 39 
conclusion, we demonstrate that CoronaHiT can multiplex up to 96 SARS-CoV-2 40 
genomes per MinION flowcell and that Illumina sequencing can be performed on the 41 
same libraries, which will allow significantly higher throughput. CoronaHiT provides 42 
increased coverage for higher Ct samples, thereby increasing the number of high quality 43 
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genomes that pass the GISAID QC threshold. This protocol will aid the rapid expansion 44 
of SARS-CoV-2 genome sequencing globally, to help control the pandemic. 45 
Introduction 46 
The COVID-19 pandemic caused by the SARS-CoV-2 virus began late 2019 in Wuhan, 47 
China and has now spread to virtually every country in the world, with tens of millions of 48 
confirmed cases and millions of deaths (Dong, Du, and Gardner 2020). Key to the control 49 
of the pandemic is understanding the epidemiological spread of the virus at global, 50 
national and local scales (Shu and McCauley 2017). Whole genome sequencing of 51 
SARS-CoV-2 is likely to be the fastest and most accurate method to study virus 52 
epidemiology as it spreads. We are sequencing SARS-CoV-2 as part of the COVID-19 53 
Genomics UK (COG-UK) consortium, a network of academic and public health 54 
institutions across the UK brought together to collect, sequence and analyse whole 55 
genomes to fully understand the transmission and evolution of this virus 56 
(https://www.cogconsortium.uk/). The SARS-CoV-2 genome was first sequenced in 57 
China using a metatranscriptomic approach (Wu et al. 2020). This facilitated the design 58 
of tiling PCR approaches for genome sequencing, the most widely used of which is the 59 
ARTIC Network (https://artic.network) protocol. Consensus genome sequences are 60 
typically made publicly available on GISAID (Elbe and BucklandMerrett 2017). This 61 
has enabled real-time public health surveillance of the spread and evolution of the 62 
pandemic through interactive tools such as NextStrain (Hadfield et al. 2018). The ARTIC 63 
network protocol was designed for nanopore technology (Oxford Nanopore 64 
Technologies), enabling rapid genome sequencing for outbreak response. The method 65 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 




was originally capable of testing only 23 samples plus a negative control on a flowcell, 66 
however, with the recent release of the Native Barcoding Expansion 96 kit by ONT, 11-67 
95 samples plus a negative control can be sequenced on a flowcell using the ARTIC 68 
LoCost V3 method (Quick, 2020). A platform agnostic method is required to provide 69 
flexible throughput on Illumina or nanopore that allows low-cost sequencing of 10s to 70 
100s of viral genomes depending on (1) changing requirements as the pandemic peaks 71 
and troughs and (2) the turnaround time required e.g. routine weekly vs rapid outbreak 72 
sequencing. Here we describe a flexible protocol, Coronavirus High Throughput 73 
(CoronaHiT), which allows for up to 95 samples, plus a negative control to be 74 
multiplexed on a single MinION flowcell or alternatively, by switching barcodes, over 75 
384 samples on Illumina. We demonstrate CoronaHiT’s performance on 95 and 59 76 
SARS-CoV-2 genomes on MinION and Illumina NextSeq for routine and rapid outbreak 77 
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Patient samples and RNA extraction 87 
Samples from cases with suspected SARS-CoV-2 were processed using five different 88 
diagnostic platforms over four laboratories in East Anglia - the Cytology Department and 89 
Microbiology Departments, NNUH, Norwich, UK, the Bob Champion Research & 90 
Education Building (BCRE), University of East Anglia, Norwich, UK and Ipswich Public 91 
Health Laboratory, Ipswich, UK. 92 
The Cytology Department processed samples using the Roche Cobas® 8800 SARS-CoV-93 
2 system (www.who.int/diagnostics_laboratory/eul_0504-046-94 
00_cobas_sars_cov2_qualitative_assay_ifu.pdf?ua=1) according to the manufacturer’s 95 
instructions (n=95). The Microbiology Department processed samples using either the 96 
Hologic Panther System Aptima® SARS-CoV-2 assay 97 
(www.fda.gov/media/138096/download) (n=25) or Altona Diagnostics RealStar® SARS-98 
CoV-s RT-PCR Kit 1.0 (altona-diagnostics.com/files/public/Content%20Homepage/-99 
%2002%20RealStar/MAN%20-%20CE%20-%20EN/RealStar%20SARS-CoV-2%20RT-100 
PCR%20Kit%201.0_WEB_CE_EN-S03.pdf) according to the manufacturer’s 101 
instructions (n=3). At the BCRE, RNA was extracted using the MagMAX™ 102 
Viral/Pathogen II Nucleic Acid Isolation kit (Applied Biosystems) according to the 103 
manufacturer’s instructions and the KingFisher Flex system (ThermoFisher). The 104 
presence of SARS-CoV-2 was determined using the 2019-nCoV CDC assay 105 
(https://www.fda.gov/media/134922/download) on the QuantStudio 5 (Applied 106 
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Biosystems) (n=7). Ipswich Public Health Laboratory processed samples using the 107 
AusDiagnostics SARS-CoV-2, Influenza and RSV 8-well panel 108 
(www.ausdx.com/qilan/Products/20081-109 
r01.1.pdf;jsessionid=5B2099CAE4D0D152C869A190D0032D71) (n=24). RNA was 110 
extracted from swab samples using either the AusDiagnostics MT-Prep (AusDiagnostics) 111 
or QIAsymphony (Qiagen) platforms according to the manufacturer’s instructions before 112 
being tested by the AusDiagnostics assay. 113 
 114 
Viral transport medium from positive swabs (stored at 4°C) was collected for all samples 115 
run on the Roche Cobas®, Hologic Panther System and Altona RealStar®. In all other 116 
cases excess RNA was collected (frozen at -80°C). Excess positive SARS-CoV-2 117 
inactivated swab samples (200µl viral transport medium from nose and throat swabs 118 
inactivated in 200 µl Zymo DNA/RNA shield and 800 µl Zymo viral DNA/RNA buffer) 119 
were collected from Cytology and the Microbiology Departments. SARS-CoV-2 positive 120 
RNA extracts (~20 µl) were collected from Ipswich Public Health Laboratory and the 121 
BCRE as part of the COG-UK Consortium project (PHE Research Ethics and 122 
Governance Group R&D ref no NR0195). RNA was extracted from inactivated swab 123 
samples using the Quick DNA/RNA Viral Magbead kit from step 2 of the DNA/RNA 124 
purification protocol (Zymo) (files.zymoresearch.com/protocols/_r2140_r2141_quick-125 
dna-rna_viral_magbead.pdf). 126 
  127 
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The lower of the cycle thresholds (Ct) produced by the two SARS-CoV-2 assays in the 128 
Roche, AusDiagnostics, Altona Diagnostics and CDC assays were used to determine 129 
whether samples required dilution before sequencing according to the ARTIC protocol. 130 
The Aptima SARS-CoV-2 assay on the Hologic Panther System does not provide a Ct 131 
value but rather a combined fluorescence signal for both targets in relative light units 132 
(RLUs), therefore all samples tested by the Hologic Panther were processed undiluted in 133 
the ARTIC protocol. 134 
 135 
ARTIC SARS-CoV-2 multiplex tiling PCR  136 
cDNA and multiplex PCR reactions were prepared following the ARTIC nCoV-2019 137 
sequencing protocol V3 (LoCost) (Quick, 2020). Dilutions of RNA were prepared when 138 
required based on Ct values following the guidelines from the ARTIC protocol. 139 
V3 CoV-2 primer scheme (https://github.com/artic-network/artic-140 
ncov2019/tree/master/primer_schemes/nCoV-2019/V3) were used to perform the 141 
multiplex PCR for SARS-CoV-2 according to the ARTIC protocol (Quick, 2020). For the 142 
ARTIC multiplex PCR, 65°C was chosen as the annealing/extension temperature, and 143 
due to variable Ct values, all samples were run for 35 cycles in the two multiplex PCRs. 144 
 145 
CoronaHiT-ONT library preparation 146 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 




Libraries were prepared using a novel modified Illumina DNA prep tagmentation 147 
approach (formerly called Nextera DNA Flex Illumina Library Prep)  (Rowan et al. 2019; 148 
Beier et al. 2017). Primers with a 3’ end compatible with the Nextera transposon insert 149 
and a 24bp barcode at the 5’ end with a 7 bp spacer were used to PCR barcode the 150 
tagmented ARTIC PCR products. The barcode sequences are from the PCR Barcoding 151 
Expansion 1-96 kit (EXP-PBC096, Oxford Nanopore Technologies). Symmetrical dual 152 
barcoding was used, i.e. the same barcode added at each end of the PCR product and up 153 
to 96 samples could be run together using this approach or 95 if a negative control is 154 
included (Supplementary Table 4). 155 
ARTIC PCR products were diluted 1:5 (2.5 µl Pool 1, 2.5 µl Pool 2 and 20 µl PCR grade 156 
water). Tagmentation was performed as follows; 0.5 µl TB1 Tagmentation Buffer 1 , 0.5 157 
µl BLT Bead-Linked Transposase (both contained in Illumina® DNA Prep, (M) 158 
Tagmentation Catalogue No 20018704) and 4 µl PCR grade water was made as a master 159 
mix scaled to sample number. On ice, 5 µl of tagmentation mix was added to each well of 160 
a chilled 96-well plate. Next, 2 µl of diluted PCR product was pipette mixed with the 5 µl 161 
tagmentation mix. This plate was sealed and briefly centrifuged before incubation at 162 
55°C for 15 minutes in a thermal cycler (heated lid 65°C) and held at 10°C. 163 
PCR barcoding was performed using Kapa 2G Robust PCR kit (Sigma Catalogue No. 164 
KK5005) as follows: 4 µl Reaction buffer (GC), 0.4 µl dNTP’s, 0.08 µl Kapa 2G Robust 165 
Polymerase and 7.52 µl PCR grade water per sample were mixed and 12 µl was added to 166 
each well in a new 96-well plate. 1 µl of the appropriate barcode pair (Supplementary 167 
Table 4) at 10µM was added to each well. Finally, the 7 µl of Tagmentation mix was 168 
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added, making sure to transfer all the beads. PCR reactions were run at 72°C for 3 169 
minutes, 95°C for 1 minute, followed by 14 cycles of 95°C for 10 seconds, 55°C for 20 170 
seconds and 72°C for 1 minute. Following PCR, 2 µl of each sample was pooled and 40 171 
µl of this pool was bead washed with 36 µl (0.8X) AMPure XP beads (2 washes in 200μl 172 
70% ethanol) for the routine samples. For the rapid response run, 100 µl of the pool was 173 
washed with 60 µl (0.6X) AMPure XP. Pools were eluted in 20 µl of EB (Qiagen 174 
Catalogue No. 19086). The barcoded pool was quantified using Qubit High Sensitivity kit 175 
(Catalogue No. Q32851). 176 
A nanopore sequencing library was then made, largely following the SQK-LSK109 177 
protocol. The end-prep reaction was prepared as follows: 7 µl Ultra II end prep buffer, 3 178 
µl Ultra II end prep enzyme mix, 40 µl nuclease free water and 10 µl of washed barcoded 179 
pool from the previous step (final volume 60 µl). The reaction was incubated at room 180 
temperature for 15 mins and 65°C for 10 mins, followed by a hold at 4°C for at least 1 181 
min. This was bead-washed using 60 µl of AMPure Beads (1X) and two 200μl 70% 182 
ethanol washes and eluted in 61 µl nuclease free water. The end-prepped DNA was taken 183 
forward to the adapter ligation as follows: 30 µl end-prepped pool from previous step 184 
(~60 ng), 30 µl nuclease free water, 25 µl LNB (ONT), 10 µl NEBNext Quick T4 Ligase 185 
and 5 µl AMX (ONT) was mixed and incubated at room temperature for 20 minutes. 186 
After the incubation, the full volume was washed with 40 µl AMPure XP beads and 2 187 
consecutive 250 µl SFB (ONT) washes with resuspension of beads both times and this 188 
was eluted in 15 µl of EB (ONT). The final library was quantified with Qubit High 189 
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Sensitivity and size checked on a Tapestation with D5000 tape. 12 µl (~30-50 ng) was 190 
used for flowcell loading, with the addition of 37.5 µl SQB and 25.5 µl LB.  191 
 192 
CoronaHiT-Illumina library preparation 193 
PCR products were tagmented and barcoded as described for the CoronaHiT-ONT library 194 
preparation, however, standard Nextera XT Index Kit indexes were used (Sets A to D for 195 
up to 384 combinations, Illumina Catalogue No’s FC-131-2001, FC-131-2002, FC-131-196 
2003 and FC-131-2004). The PCR master mix was adjusted and water removed to add 2 197 
µl each of the P7 and P5 primers. Five microliters of each barcoded sample was pooled 198 
(without quantification) and 100 µl  of the library pool was size selected with 0.8X 199 
AMPure XP beads (80 µl), with final elution in 50 µl EB (10mM Tris-HCl). The 200 
barcoded pool was sized on a Agilent Tapestation D5000 tape and quantified using 201 
QuantiFluor® ONE dsDNA System (Promega, WI, USA) and the molarity calculated. 202 
The Illumina library pool was run at a final concentration of 1.5 pM on an Illumina 203 
Nextseq500 instrument using a Mid Output Flowcell (NSQ® 500 Mid Output KT v2 204 
(300 CYS) Illumina Catalogue FC-404-2003) following the Illumina recommended 205 
denaturation and loading recommendations which included a 1% PhiX spike (PhiX 206 
Control v3 Illumina Catalogue FC-110-3001).  207 
 208 
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ARTIC LoCost protocol Nanopore library preparation 209 
After ARTIC multiplex PCR, library preparation was performed using the nCoV-2019 210 
sequencing protocol v3 (LoCost) V3 (Quick, 2020). Briefly, PCR Pool 1 and 2 were 211 
pooled for each sample and diluted 1 in 10 (2.5 µl Pool 1, 2.5 µl Pool 2 and 45 µl 212 
nuclease free water), and end-prepped as follows: 1.2 µl Ultra II end prep buffer, 0.5 µl 213 
Ultra II end prep enzyme mix, 3.3 µl PCR dilution from previous step and 5 µl nuclease 214 
free water (final volume 15 µl). The reaction was incubated at room temperature for 15 215 
min and 65°C in a thermocycler for 15 min and incubated on ice for 1 min. Native 216 
barcode ligation was prepared in a new plate: 0.75 µl end-prepped DNA,  1.25 µl native 217 
barcode, 5 µl Blunt/TA Ligase Master Mix, 3 µl nuclease free water, (final volume 10 218 
µl). The reaction was incubated at room temperature 20 min and 65°C in a thermocycler 219 
for 10 min and incubated on ice for 1 min. Amplicons were pooled together (2 µl for 95 220 
samples and 5 µl for 59 samples) and underwent a 0.4X AMPure bead wash with two 250 221 
µl SFB washes and one 70% ethanol wash. DNA was eluted in 30 µl of Qiagen EB. 222 
Adapter ligation was performed on the full volume (30 µl barcoded amplicon pool, 5 µl 223 
Adapter Mix II (ONT), 10 µl NEBNext Quick Ligation Reaction Buffer (5X), 5 µl Quick 224 
T4 DNA Ligase). The ligation reaction was incubated at room temperature for 20 min 225 
and 1X bead washed (50 µl AMPure XP beads) with 250 µl SFB two times. The library 226 
was eluted in 15 µl of elution buffer (ONT) and quantified. 15 ng of the adapted library 227 
was used for final loading.  228 
 229 
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Nanopore sequence analysis 230 
Basecalling was performed using Guppy v.4.2.2 (Oxford Nanopore Technologies) in high 231 
accuracy mode (model dna_r9.4.1_450bps_hac), on a private OpenStack cloud at 232 
Quadram Institute Bioscience using multiple Ubuntu v18.04 virtual machines running 233 
Nvidia T4 GPU.  234 
 235 
The CoronaHiT-ONT sequencing data were demultiplexed using guppy_barcoder 236 
(v4.2.2) with a custom arrangement of the barcodes as described at 237 
https://github.com/quadram-institute-bioscience/coronahit_guppy, with the option 238 
‘require_barcodes_both_ends’ and a score of 60 at both ends to produce 95 FASTQ files 239 
(94 SARS-CoV-2 samples and 1 negative control) and 61 FASTQ files (59 SARS-CoV-2 240 
samples and 2 negative control) for the routine and rapid response runs, respectively. The 241 
ARTIC ONT sequencing data were demultiplexed using guppy_barcoder (v4.2.2) with 242 
the option ‘require_barcodes_both_ends’ and a score of 60 at both ends to produce 95 243 
FASTQ files (94 SARS-CoV-2 samples and 1 negative control) and 61 FASTQ files (59 244 
SARS-CoV-2 samples and 2 negative control) for the routine and rapid response runs, 245 
respectively. 246 
 247 
The downstream analysis was performed using a copy of the ARTIC pipeline (v1.1.3) as 248 
previously described (Loman, Rowe, and Rambaut 2020) to generate a consensus 249 
sequence for each sample in FASTA format. The pipeline includes the following main 250 
steps: The input reads were filtered based on reads length (ARTIC: 400-700; CoronaHiT: 251 
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150-600), and mapped to the Wuhan-Hu-1 reference genome (accession MN908947.3) 252 
using minimap2 (v 2.17-r941). The mapped bases in BAM format were trimmed off in 253 
primer regions by the ARTIC subcommand align_trim for ARTIC LoCost data. For 254 
CoronaHiT-ONT data, we used the subcommand samtools ampliconclip (v 1.11) at the 255 
primer trimming step (https://github.com/quadram-institute-256 
bioscience/fieldbioinformatics/tree/coronahit). The trimmed reads were then used for 257 
variant calling with medaka (v 1.2.0) and longshot (v 0.4.1). The final consensus was 258 
generated from a filtered VCF file and a mask file of positions with either a depth of 259 
coverage lower than 20 or a SNP in an amplifying primer site. The consensus sequences 260 
were uploaded to GISAID and the raw sequence data was uploaded to the European 261 
Nucleotide Archive under BioProject PRJEB41737. The accession numbers for each 262 
sample are available in Supplementary Table 1. The metrics and results of all 263 
experiments are available in Supplementary Table 2 and are summarised in Table 1. 264 
 265 
Illumina sequence analysis 266 
Additional samples, not reported in this study, were included on Illumina NextSeq runs. 267 
The raw reads were demultiplexed using bcl2fastq (v2.20) (Illumina Inc.) to produce 311 268 
FASTQ files for the run with the routine samples (112 SARS-CoV-2 samples and 3 269 
negative controls) and the run with the rapid response samples (247 SARS-CoV-2 270 
samples, 4 negative controls, and 2 positive controls) with only the relevant samples 271 
analysed in this paper. The reads were used to generate a consensus sequence for each 272 
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sample using an open source pipeline adapted from https://github.com/connor-273 
lab/ncov2019-artic-nf ( 274 
https://github.com/quadram-institute-bioscience/ncov2019-artic-nf/tree/qib). Briefly, the 275 
reads had adapters trimmed with TrimGalore 276 
(https://github.com/FelixKrueger/TrimGalore), were aligned to the Wuhan-Hu-1 277 
reference genome (accession MN908947.3) using BWA-MEM (v0.7.17) (Li 2013), the 278 
ARTIC amplicons were trimmed and a consensus built using iVAR (v.1.2.3) (Grubaugh 279 
et al. 2019). 280 
 281 
Quality Control 282 
The COG-UK consortium defined a consensus sequence as passing COG-UK quality 283 
control if greater than 50% of the genome was covered by confident calls or there was at 284 
least 1 contiguous sequence of more than 10,000 bases and with no evidence of 285 
contamination.  This is regarded as the minimum amount of data to be phylogenetically 286 
useful. A confident call was defined as having a minimum of 10X depth of coverage for 287 
Illumina data and 20X depth of coverage for Nanopore data. If the coverage fell below 288 
these thresholds, the bases were masked with Ns.  Low quality variants were also masked 289 
with Ns. The QC threshold for inclusion in GISAID was higher, requiring that greater 290 
than 90% of the genome was covered by confident calls with no evidence of 291 
contamination. 292 
 293 
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Phylogenetic analysis 294 
For each sample sequenced in 3 separate experiments (CoronaHiT-ONT, CoronaHiT-295 
Illumina, ARTIC-ONT), a phylogeny was generated from all of the consensus genomes 296 
(n=216 for the routine samples and n=132 for the rapid response samples) passing 297 
GISAID QC over all experiments (n=72 out of 95, and n=44 out of 59). A multiple 298 
FASTA alignment was created by aligning all samples to the reference genome 299 
MN908947.3 with MAFFT v7.470. A maximum likelihood tree was estimated with 300 
IQTREE2 (v2.0.4) (Minh et al. 2020) under the HKY model (Hasegawa, Kishino, and 301 
Yano 1985), collapsing branches smaller than 10-7 into a polytomy. SNPs in the multiple 302 
FASTA alignment were identified using SNP-sites (v2.5.1) (Page et al. 2016) and the tree 303 
was visualised with FigTree (v1.4.4) (https://github.com/rambaut/figtree).  304 
 305 
Results 306 
A novel library preparation method, CoronaHiT, was developed for SARS-CoV-2 307 
genome sequencing, which combines a cheap transposase-based introduction of adapters 308 
(Illumina Nextera) with symmetric PCR barcoding of up to 96 samples (or 95 samples 309 
with a negative control) on a MinION. Alternatively, if higher throughput is needed, the 310 
barcodes can be switched for Illumina sequencing. For ONT sequencing, Nextera adapter 311 
complementary primer sequences were added to ONT PCR barcodes and used to barcode 312 
ARTIC PCR products (Figure 1) as described in the methods. For Illumina sequencing, 313 
the method is a streamlined and cheaper version of standard Illumina library preparations. 314 
CoronaHiT does not require individual sample washes and allows samples to be 315 
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processed uniformly without quantification or normalisation as with the ARTIC LoCost 316 
method.  317 
 318 
The CoronaHiT method was tested by multiplexing 95 SARS-CoV-2 routine COG-UK 319 
samples plus a blank (hereinafter referred to as the Routine Samples) on a MinION 320 
flowcell and on an Illumina NextSeq run. Another 59 samples, including 18 query 321 
outbreak samples, plus blanks (hereinafter referred to as the Rapid Response samples) 322 
were rapidly sequenced (within 24 hrs of receipt, with results available the following day) 323 
on a second flowcell, as well as on Illumina NextSeq. All samples were also sequenced 324 
using the ARTIC LoCost library preparation protocol on the MinION for comparison. 325 
For the routine samples, 30 hours of sequencing data was used for both CoronaHiT-ONT 326 
and ARTIC LoCost, and for the rapid response set, 18 hours was used; the full dataset 327 
was used for both CoronaHiT-Illumina runs. The different methods produced different 328 
amounts of demultiplexed data. For the routine samples, CoronaHiT-ONT yielded 9.6 329 
Gbases of sequence data, ARTIC LoCost sequencing produced 8.0 Gbases of data, and 330 
CoronaHiT-Illumina yielded 15.7 Gbases giving on average 1145X, 1719X and 4649X  331 
coverage per sample (Table 1). For the rapid response dataset, CoronaHiT-ONT 332 
produced 5.7 Gbases, ARTIC LoCost 4.5 Gbases, and CoronaHiT-Illumina 7.3 Gbases 333 
resulting in 1104X, 1421X, and 3010X coverage per sample respectively. Both 334 
CoronaHiT-ONT runs had less variation in coverage between samples compared to the 335 
ARTIC LoCost runs, with lower standard deviation relative to the mean (Table 1). The 336 
lower coverage for CoronaHiT-ONT compared to ARTIC is related to the shorter read 337 
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lengths and the increased proportion of barcode/adapter sequence in each read and, 338 
hence, the reduced mappable region of each read.  339 
 340 
Taking all the genomes which passed COG-UK QC, the CoronaHiT-Illumina sequencing 341 
runs produced the shortest mappable mean read length at 135 and 131 bases for the 342 
routine samples and rapid response samples respectively, just short of the maximum 150 343 
bases for the PE 151 chemistry; ARTIC LoCost produced 386 and 384 bases, and 344 
CoronaHiT-ONT sequencing produced mappable mean read lengths of 205 and 241 345 
bases. The shorter read lengths for CoronaHiT are related to the use of bead-linked 346 
transposases for tagmentation, resulting in the removal of the ends of the ARTIC PCR 347 
products. The introduction of a 0.6X bead wash for the rapid response CoronaHiT-ONT 348 
run (instead of the 0.8X bead wash for the routine run) resulted in the longer mapped 349 
reads and contributed to a reduction in the difference in average coverage between 350 
CoronaHiT and ARTIC (from 1145x vs 1719x in routine run dropping to 1104X vs 351 
1421X in the rapid response run, with similar ratios of raw data produced by the methods 352 
in the two runs).  353 
 354 
The demultiplexing steps for CoronaHiT-ONT were different from those used for ARTIC 355 
ONT sequencing as described in the methods section. Comparing the nanopore 356 
sequencing methods for the routine samples, 74.7% and 81.9% of reads were 357 
demultiplexed successfully for CoronaHiT-ONT and ARTIC LoCost respectively when 358 
only reads with a PHRED (quality) score above Q7 are considered; for the rapid response 359 
set,  69.6% and 71.6% were demultiplexed for CoronaHiT-ONT and ARTIC LoCost. The 360 
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rest of the reads were unassigned, due to an inability to detect the barcode sequences at 361 
both ends of the reads. The negative controls contained zero mapping reads to SARS-362 
CoV-2 for all nanopore datasets. The Illumina routine dataset had mapped reads, 363 
however, the vast majority were primers dimers (range of 0-4 SARS-CoV-2 reads >40bp 364 
mapped out of the 3 negative controls). 365 
 366 
Poor quality consensus genomes were generally associated with a lower SARS-CoV-2 367 
viral load in the clinical samples i.e. higher RT-qPCR Ct values (generally above Ct 32) 368 
were more likely to fail COG-UK and GISAID quality control thresholds. For all 369 
methods the number of Ns increased significantly in samples with a Ct above 32, which 370 
equates to approx 100 viral genome copies in the PCR reaction (Figure 2). 371 
Supplementary Figures 1a-f show the Ns (missing or masked bases) within the consensus 372 
genomes - the three ARTIC PCR primer dropout areas (Benjamin Farr et al. 2020) are 373 
clearly visible. Comparing the routine samples with a Ct of 32 or below (n=65; Cts for 374 
most rapid response samples were unknown), the mean (median) number of Ns was 815 375 
(121) for ARTIC LoCost, 111 (47) for CoronaHiT-Illumina, and 682 (339) for 376 
CoronaHiT-ONT. If all samples are included for the routine set (including higher Ct 377 
samples) then the number of Ns increases substantially to a mean (median) of 1635 (121) 378 
bases for ARTIC LoCost, 688 (53) for CoronaHiT-Illumina and 1504 (359) for 379 
CoronaHiT-ONT. 380 
 381 
The number of samples passing the COG-UK QC criteria was 73 for ARTIC LoCost, 76 382 
for CoronaHiT-ONT and 78 for CoronaHiT-Illumina in the routine set and 44 for ARTIC 383 
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LoCost, and 48 for both CoronaHiT-ONT and CoronaHiT-Illumina in the rapid response 384 
set. The stricter GISAID QC criteria reduces the number of samples passing QC, with the 385 
CoronaHiT method outperforming ARTIC LoCost. For the routine samples, 59 samples 386 
passed for ARTIC LoCost, 66 passed for CoronaHiT-ONT and 74 passed for CoronaHiT-387 
Illumina and for the rapid response set 40 passed for ARTIC LoCost, and 44 passed for 388 
both CoronaHiT-ONT and CoronaHiT-Illumina. Overall, the pass rate was 64.3% for 389 
ARTIC LoCost, 71.4% for CoronaHiT-ONT and 76.6% for CoronaHiT-Illumina. When 390 
considering higher viral load samples with a known Ct of 32 or below, the pass rate for 391 
both GISAID and COG-UK QC was higher, with 89.2% passing for ARTIC LoCost and  392 
95.2% and 97.6% passing for CoronaHiT-ONT and CoronaHiT-Illumina, respectively 393 
(full details are shown in Table 2). CoronaHiT-ONT had a higher pass rate compared to 394 
ARTIC LoCost even though the average coverage was lower, this related to more even 395 
coverage across samples on the flowcell (lower standard deviation between samples 396 
relative to the mean - Table 1). 397 
 398 
To assess the impact of data quality differences on clustering of lineages, we built 399 
maximum likelihood trees for both the routine and rapid response runs with each of the 400 
72 and 44 consensus genomes that passed QC from the ARTIC LoCost, CoronaHiT-ONT 401 
and CoronaHiT-Illumina sequencing experiments. When the consensus genomes were 402 
placed on a phylogenetic tree for the routine set, CoronaHiT-Illumina, ARTIC LoCost, 403 
CoronaHiT-ONT showed the same clustering for most samples, except for three cases 404 
(EB1DB, EC741 and EC644) where we note that their ARTIC LoCost consensus show 405 
an increased number of ambiguous bases. All variant differences between the samples are 406 
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noted in Supplementary Table 3, together with the sequence length (discounting 407 
ambiguous bases whenever there is a difference). Out of all samples in both datasets, 408 
there were only two SNP discrepancies, one in sample F04F8 between CoronaHiT-ONT 409 
and CoronaHiT-Illumina, with ARTIC LoCost calling the SNP ambiguous, and in sample 410 
F0A23 with CoronaHiT-ONT disagreeing with the other methods (Supplementary Table 411 
3). The SNP differences did not affect the classification (i.e. closest sequence in the 412 
database), and there were no SNP differences between ARTIC-ONT and CoronaHiT-413 
Illumina. The main other source of variation between the samples is that the Illumina 414 
genomes allow IUPAC (IUPAC-IUB Comm. on Biochem. Nomenclature (CBN) 1970) 415 
symbols for “partially” ambiguous bases. These data show that CoronaHiT provides 416 
highly accurate lineage calling compared to ARTIC LoCost. 417 
 418 
The average number of SNPs between the Wuhan-Hu-1 reference genome and the 419 
consensus genomes varied between 7.99 SNPs for and 11.00 SNPs for the routine 420 
samples, and 18.2 and 20.4 SNPs for the rapid response samples across all methods (see 421 
Table 2 and Supplementary Table 2). The mean number of SNPs in CoronaHiT-Illumina 422 
was higher compared to the two ONT sequencing methods (Table 2) due to ambiguous 423 
bases in the Illumina dataset being regarded as SNPs in these calculations (Table 2). 424 
 425 
The reagent cost per sample for CoronaHiT-ONT was £8.46 when sequencing 95 426 
samples and a negative control on a MinION flowcell, marginally cheaper but similar to 427 
ARTIC sequencing at £9.75 per sample (cost breakdown in Supplementary Table 5). If 428 
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384 samples are sequenced on an Illumina NextSeq Mid output run with the CoronaHiT 429 
library preparation method, the per sample cost is £5.62.  430 
 431 
Discussion 432 
Rapid viral genome sequencing during outbreaks is changing how we study disease 433 
epidemiology (Kafetzopoulou et al. 2019; Joshua Quick et al. 2016). The recent SARS-434 
CoV-2 global pandemic has again highlighted the use of sequencing in the control of the 435 
spread of the disease. Nanopore technology is particularly suited to outbreak sequencing 436 
as it is portable, does not require expensive machinery and is accessible throughout the 437 
world (Faria et al. 2016). We present a novel platform agnostic method, CoronaHiT, for 438 
flexible throughput, cost effective and low complexity sequencing of SARS-CoV-2 439 
genomes to respond to the pandemic at the local and national level. 440 
 441 
The ARTIC LoCost protocol (Quick, 2020) has been widely adopted for SARS-CoV-2 442 
genome sequencing and allows up to 95 samples (plus a negative control) to be 443 
sequenced at a time on a MinION. CoronaHiT is just as cheap, simple and fast, but the 444 
combination of transposase introduction of adapters with PCR based barcoding allows for 445 
more even coverage between multiplexed samples, resulting in a higher proportion of 446 
samples passing QC. It is also designed to be platform agnostic, simply switching 447 
barcodes to move to Illumina. This allows the user to flexibly sequence low or high 448 
throughput depending on rapidly changing requirements in the pandemic (Bayliss et al. 449 
2017; Josh Quick 2020). With the use of asymmetric barcode primers described in Perez-450 
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Sepulveda et al. 2020, it is possible to sequence SARS-CoV-2 at very high throughput on 451 
Illumina; in fact we have recently sequenced over 1000 SARS-CoV-2 genomes on a 452 
single Illumina NextSeq High Output run using this approach (data not shown). The 453 
CoronaHiT-Illumina library preparation method is cheaper (reduced reaction volumes) 454 
and significantly more streamlined (no sample washing or quantification before pooling, 455 
no use of stop solution, no clean-up after tagmentation and no clean-up of barcoded PCR 456 
products) than standard Illumina library preparation. 457 
 458 
Tiling PCR approaches, such as ARTIC, are prone to high genome coverage variation 459 
due to variable primer efficiency in multiplex reactions. Some regions of the SARS-CoV-460 
2 genome have hundreds of times higher coverage than adjacent regions using ARTIC, 461 
therefore average coverage of at least 1000X is required to obtain at least 20X coverage 462 
of the difficult regions of the genome. We demonstrate that we can achieve >1000X 463 
SARS-CoV-2 genome coverage in ~20 minutes per sample using CoronaHiT-ONT on 464 
MinION, with a full set of 95 samples taking ~30 hours). While the CoronaHiT-ONT 465 
runs described here are very consistent, sequencing yield depends on flowcell quality. We 466 
recommend aiming for at least 100 Mbases of estimated sequencing yield per sample to 467 
provide sufficient data for >1000X coverage/sample (average across flowcell) using 468 
CoronaHiT-ONT. 469 
 470 
Results demonstrate that all methods are unreliable at producing high quality consensus 471 
genomes from positive clinical samples with diagnostic RT-qPCR Cts above 32 (approx. 472 
100 viral genome copies), however, CoronaHiT performs better in these samples (Figure 473 
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2), producing fewer Ns, likely due to the additional rounds of PCR during barcoding. 474 
Below or equal to Ct 32, CoronaHiT-ONT, CoronaHiT-Illumina and ARTIC LoCost 475 
produce similar results. While more samples pass both QC measures with CoronaHiT-476 
ONT and CoronaHiT-Illumina compared to ARTIC LoCost, primer dropout regions can 477 
be more pronounced in these methods (Supplementary Figure 1). For higher quality 478 
consensus genomes, sequencing may be run for longer. Additionally, a reduction in 479 
ARTIC PCR annealing temperature from 65°C to 63°C may help improve coverage 480 
across these regions (Benjamin Farr et al. 2020). However, data produced from 481 
CoronaHiT was sufficient to provide accurate consensus genomes that result in the same 482 
lineages and on the same branches on the phylogenetic tree as ARTIC LoCost (Figure 3). 483 
Therefore, we have demonstrated high quality, multiplexed SARS-CoV-2 genome 484 
sequencing of 95 samples on a single flowcell. If the ARTIC PCR step is optimised to 485 
even the coverage of the amplicons (as demonstrated in the Sanger COVID-19 ARTIC 486 
Illumina protocol (Benjamin Farr et al. 2020)), less overall coverage will be required per 487 
genome and more samples can be multiplexed using all methods. 488 
 489 
In conclusion, we demonstrate that CoronaHiT can be used to sequence 96 SARS-CoV-2 490 
samples on a single MinION flowcell, with the option of higher throughput on Illumina. 491 
This platform agnostic method is simple, rapid and cheap and results in more samples 492 
passing QC than ARTIC LoCost while providing almost identical phylogenetic results.  493 
CoronaHiT can help scientists around the world sequence SARS-CoV-2 genomes with 494 
highly flexible throughput, thereby increasing our understanding, and reducing the 495 
spread, of the pandemic. 496 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 





Ethical approval 498 
The COVID-19 Genomics UK Consortium has been given approval by Public Health 499 
Englands Research Ethics and Governance Group (PHE R&D Ref: NR0195). 500 
 501 
Acknowledgements 502 
Thanks to George Taiaroa and Torsten Seemann from the Microbiological Diagnostic 503 
Unit Public Health Laboratory at the University of Melbourne for their advice and 504 
assistance, to Niamh Tumelty from the University of Cambridge for assistance and to 505 
Darren Heavens from the Earlham Institute for his advice on library preparation.  Thanks 506 
to the COG-UK Consortium Study Group for their contributions. 507 
 508 
Funding statement 509 
The authors gratefully acknowledge the support of the Biotechnology and Biological 510 
Sciences Research Council (BBSRC); this research was funded by the BBSRC Institute 511 
Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent 512 
projects BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, and 513 
BBS/E/F/000PR10352. DJB, NFA, TLV and AJP were supported by the Quadram 514 
Institute Bioscience BBSRC funded Core Capability Grant (project number 515 
BB/CCG1860/1). EMA was funded by the BBSRC Institute Strategic Programme Gut 516 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 




Microbes and Health BB/R012490/1 and its constituent project(s) BBS/E/F/000PR10353 517 
and BBS/E/F/000PR10356.  The sequencing costs were funded by the COVID-19 518 
Genomics UK (COG-UK) Consortium which is supported by funding from the Medical 519 
Research Council (MRC) part of UK Research & Innovation (UKRI), the National 520 
Institute of Health Research (NIHR) and Genome Research Limited, operating as the 521 
Wellcome Sanger Institute. The author(s) gratefully acknowledge the UKRI 522 
Biotechnology and Biological Sciences Research Council’s (BBSRC) support of The 523 
Norwich Research Park Biorepository. LG was supported by a DART MRC iCASE and 524 
Roche Diagnostics. APT was funded by Sara Borrell Research Grant CD018/0123 from 525 
ISCIII and co-financed by the European Development Regional Fund (A Way to Achieve 526 
Europe program) and APT QIB internship additionally funded by "Ayuda de la SEIMC". 527 
The funders had no role in study design, data collection and analysis, decision to publish, 528 
or preparation of the manuscript.  529 
 530 
Financial declaration 531 
LG received a partial support for his PhD from Roche. The use of Roche technology for 532 
diagnostics in NNUH is coincidental. 533 
 534 
Author contributions 535 
All authors have read this manuscript and consented to its publication. The CoronaHiT 536 
method was developed by DJB and AA. The study was designed and conceived by DJB, 537 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 




JOG, AJP. Paper writing was by DJB, AA, AJP, JOG, GLK, APT, TLV, SR, LM. 538 
Sequencing and library preparation was performed by DJB, AA, SR, GLK, APT, AB, 539 
AJT, NMT, RG, JOG. Bioinformatics analysis and informatics were performed by TLV, 540 
LOM, NFA, AJP. Clinical diagnostics and extractions were managed by AK, SD, RP, 541 
NE, EM. Samples and metadata were collected by LG, AB, AVG, EMA, AK and MD 542 
and biobanked by RS, RNA was extracted by AB, AJT. Risk assessments were by GLK, 543 
JW. Project management and oversight was by GLK, JOG, AJP, LM, MW, AEM, JW. 544 
Funding for the project was secured by JOG, AJP, IGC.545 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 





AusDiagnostics. 2020. ‘SARS-COV-2, INFLUENZA AND RSV 8-WELL’. 20081. 
https://www.ausdx.com/qilan/Products/20081-r01.1.pdf. 
Bayliss, Sion C., Vicky L. Hunt, Maho Yokoyama, Harry A. Thorpe, and Edward J. Feil. 
2017. ‘The Use of Oxford Nanopore Native Barcoding for Complete Genome 
Assembly’. GigaScience 6 (3). https://doi.org/10.1093/gigascience/gix001. 
Beier, Sebastian, Axel Himmelbach, Christian Colmsee, Xiao-Qi Zhang, Roberto A. 
Barrero, Qisen Zhang, Lin Li, et al. 2017. ‘Construction of a Map-Based 
Reference Genome Sequence for Barley, Hordeum Vulgare L.’ Scientific Data 4 
(1): 170044. https://doi.org/10.1038/sdata.2017.44. 
Benjamin Farr, Diana Rajan, Emma Betteridge, Lesley Shirley, Michael Quail, Naomi 
Park, Nicholas Redshaw, et al. 2020. ‘COVID-19 ARTIC v3 Illumina Library 
Construction and Sequencing Protocol’, May. 
https://doi.org/10.17504/protocols.io.bgq3jvyn. 
Dong, Ensheng, Hongru Du, and Lauren Gardner. 2020. ‘An Interactive Web-Based 
Dashboard to Track COVID-19 in Real Time’. The Lancet Infectious Diseases 0 
(0). https://doi.org/10.1016/S1473-3099(20)30120-1. 
Elbe, Stefan, and Gemma BucklandMerrett. 2017. ‘Data, Disease and Diplomacy: 
GISAID’s Innovative Contribution to Global Health’. Global Challenges 1 (1): 
33–46. https://doi.org/10.1002/gch2.1018. 
Grubaugh, Nathan D., Karthik Gangavarapu, Joshua Quick, Nathaniel L. Matteson, 
Jaqueline Goes De Jesus, Bradley J. Main, Amanda L. Tan, et al. 2019. ‘An 
Amplicon-Based Sequencing Framework for Accurately Measuring Intrahost 
Virus Diversity Using PrimalSeq and IVar’. Genome Biology 20 (1): 8. 
https://doi.org/10.1186/s13059-018-1618-7. 
Hasegawa, Masami, Hirohisa Kishino, and Taka-aki Yano. 1985. ‘Dating of the Human-
Ape Splitting by a Molecular Clock of Mitochondrial DNA’. Journal of 
Molecular Evolution 22 (2): 160–74. https://doi.org/10.1007/BF02101694. 
IUPAC-IUB Comm. on Biochem. Nomenclature (CBN). 1970. ‘Abbreviations and 
Symbols for Nucleic Acids, Polynucleotides, and Their Constituents’. 
Biochemistry 9 (20): 4022–27. https://doi.org/10.1021/bi00822a023. 
Kafetzopoulou, L. E., S. T. Pullan, P. Lemey, M. A. Suchard, D. U. Ehichioya, M. 
Pahlmann, A. Thielebein, et al. 2019. ‘Metagenomic Sequencing at the Epicenter 
of the Nigeria 2018 Lassa Fever Outbreak’. Science (New York, N.Y.) 363 (6422): 
74–77. https://doi.org/10.1126/science.aau9343. 
Li, Heng. 2013. ‘Aligning Sequence Reads, Clone Sequences and Assembly Contigs with 
BWA-MEM’. ArXiv:1303.3997 [q-Bio], March. http://arxiv.org/abs/1303.3997. 
Loman, Nicholas J., Will Rowe, and Andrew Rambaut. 2020. ‘NCoV-2019 Novel 
Coronavirus Bioinformatics Protocol’. v1.1.0. https://artic.network/ncov-
2019/ncov2019-bioinformatics-sop.html. 
Minh, Bui Quang, Heiko A. Schmidt, Olga Chernomor, Dominik Schrempf, Michael D. 
Woodhams, Arndt von Haeseler, and Robert Lanfear. 2020. ‘IQ-TREE 2: New 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 




Models and Efficient Methods for Phylogenetic Inference in the Genomic Era’. 
Molecular Biology and Evolution, February. 
https://doi.org/10.1093/molbev/msaa015. 
Page, Andrew J., Ben Taylor, Aidan J. Delaney, Jorge Soares, Torsten Seemann, 
Jacqueline A. Keane, and Simon R. Harris. 2016. ‘SNP-Sites: Rapid Efficient 
Extraction of SNPs from Multi-FASTA Alignments’. Microbial Genomics 2 (4): 
e000056. https://doi.org/10.1099/mgen.0.000056. 
Perez-Sepulveda, B.M., Heavens, D., Pulford, C.V., Predeus, A.V., Low, R., Webster, H., 
Schudoma, C., Rowe, W., Lipscombe, J., Watkins, C., et al. (2020). An accessible, 
efficient and global approach for the large-scale sequencing of bacterial 
genomes. BioRxiv 2020.07.22.200840. 
Quick, Josh. 2020. ‘NCoV-2019 Sequencing Protocol V2’, April. 
https://doi.org/10.17504/protocols.io.bdp7i5rn. 
Quick, Joshua. 2020b. ‘NCoV-2019 Sequencing Protocol V3’, August, 2020. 
https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-
bh42j8ye. 
Quick, Joshua, Nicholas J. Loman, Sophie Duraffour, Jared T. Simpson, Ettore Severi, 
Lauren Cowley, Joseph Akoi Bore, et al. 2016. ‘Real-Time, Portable Genome 
Sequencing for Ebola Surveillance’. Nature 530 (7589): 228–32. 
https://doi.org/10.1038/nature16996. 
Rowan, Beth A., Darren Heavens, Tatiana R. Feuerborn, Andrew J. Tock, Ian R. 
Henderson, and Detlef Weigel. 2019. ‘An Ultra High-Density Arabidopsis 
Thaliana Crossover Map That Refines the Influences of Structural Variation and 
Epigenetic Features’. Genetics 213 (3): 771–87. 
https://doi.org/10.1534/genetics.119.302406. 
Shu, Yuelong, and John McCauley. 2017. ‘GISAID: Global Initiative on Sharing All 





.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 





Table 1: Summary statistics for each sequencing experiment. Sample specific metrics are 
available in Supplementary Table 2. (*The CoronaHiT-Illumina total yield includes non-

















No. of samples 95 95 95 59 59 59 
Run time (h) 30 30 25.4 18 18 24.4 
Yielded bases 
(Gb) 






























13.47 13.11 33.15 13.2 12.98 33.48 
Average 
coverage (X) 




698X 1683X 4352X 439X 1145X 3496X 
Average read 
length (bases) 
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66 59 74 44 40 44 
 
Table 2: The number of consensus genomes passing and failing the different QC 
thresholds for each experiment. Extended data are available in Supplementary Table 2. 
 
 













No. of samples 
sequenced 







100% (95) 96.61% (57) 91.53% (54) 100% (59) 
Passing COG-
UK QC 




81.36% (48) 74.58% (44) 81.36% (48) 
Passing GISAID 
QC 




74.58% (44) 67.80% (40) 74.58%(44) 
Failing COG-UK 
QC 











25.42%(15) 32.20% (19) 25.42% (15) 
Avg (Median)  
Ns of COG-UK 
passed 
1504 (354) 1635 
(121) 
688 (53) 977 (606) 1101 (339) 911 (292) 
Avg SNPs of 
COG-UK 
passed 
7.99 7.99 11.0 18.3 18.2 20.4 
No. of samples 
with known Ct 
≤32 
65 65 65 18 18 18 
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100% (65) 100% 
(65) 
100% (65) 100% (18) 100% (18) 100% (18) 
Passing COG-
UK QC 




100%(18) 94.44% (17) 100% (18) 
Passing GISAID 
QC 




94.44% (17) 88.89% (16) 94.44% (17) 
Failing COG-UK 
QC 
1.54% (1) 1.54% (1) 1.54% (1) 0% (0) 5.56% (1) 0% (0) 
Failing GISAID 
QC 
4.62% (3) 10.77% 
(7) 
1.54% (1) 5.56% (1) 11.11% (2) 5.56% (1) 
Avg (Median) Ns 
of COG-UK 
passed 
682 (339) 815 (121) 111 (47) 895 (339) 911 (121) 1064 (514) 
Avg SNPs of 
COG-UK 
passed 
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Figure 2: Ct value of the SARS-CoV-2 positive RNA samples sequenced using all three 
sequencing methods vs total number of Ns in the consensus sequence for the (a) routine 
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Figure 3: Maximum likelihood tree of the consensus genomes from each sequencing 
methods, showing agreement between methods for the (a) routine samples and (b) rapid 
response samples. 
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